Bruno Larvol is the founder of The Larvol Group. Larvol has more than 15 years of successful experience in the pharmaceutical and biotechnology industries. He has worked previously with industry leaders such as The Wilkerson Group / IBM Healthcare Consulting, Lehman Brothers, Sandoz (Novartis), and Abbott. Mr. Larvol founded and served as Chief Executive Officer of Cognia. He serves on the Biotechnology Advisory Board of the Kellogg Graduate School of Management. He holds an MBA with distinction from the Kellogg School of Management and an MS in biotechnology from Northwestern University.
In founding Larvol, Bruno focused on creating a workforce platform that could deliver customized solutions to the pharmaceutical industry. He has grown the company to over 60 employees and has maintained profitability year over year without external investment. His interest in the intersection between health and data began early in his career at IBM, where he worked as a Senior Consultant in Healthcare Global Services. After his time at IBM, Bruno founded and served as CEO of Cognia, a bioinformatics company. He holds an MBA with distinction from the Kellogg School of Management, an MS in Biotechnology from Northwestern University, and an undergraduate degree with distinction from Sorbonne University in Paris. Bruno lives in San Francisco with his wife Wan, and their son Bradlen.
